A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Serplulimab,Gastric Cancer, Adjuvant Therapy
Interventions
DRUG

Serplulimab

Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

DRUG

Docetaxel

40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

DRUG

S1

Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Trial Locations (1)

Unknown

RECRUITING

Zhang Zizhen, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER